Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms
- PMID: 1396327
- DOI: 10.1210/endo.131.4.1396327
Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms
Abstract
Insulin secretion was studied in rat pancreatic islets after 24-h exposure to various glyburide or tolbutamide concentrations. Glucose-induced insulin release was significantly (P < 0.05) reduced in islets cultured with 0.1 microM glyburide or 100 microM tolbutamide (2098 +/- 187, 832 +/- 93, and 989 +/- 88 pg/islet.h in control, glyburide-exposed, and tolbutamide-exposed islets, respectively). When glyburide-treated islets were stimulated with glyburide or tolbutamide, insulin release was also impaired compared to that in control islets (P < 0.05). In contrast, tolbutamide-exposed islets showed an impaired response to tolbutamide, but a normal response to glyburide. To investigate the mechanism of the sulfonylurea-induced impairment of insulin secretion, we measured insulin release and Rb+ efflux (a marker of the K+ channel activity) in a perifusion system and islet Ca2+ uptake under static conditions. Insulin release in response to 16.7 mM glucose increased in control islets from 9.4 +/- 1.1 to 131 +/- 19 pg/islet.min (first phase secretion peak). Simultaneously, the fractional 86Rb+ efflux declined from 0.015 +/- 0.002% to 0.006 +/- 0.001% (change in decrement, -63.5%). Glucose-induced insulin release in glyburide- and tolbutamide-treated islets was significantly reduced (first phase peak, 22.1 +/- 5 and 39.7 +/- 8 pg/islet.min, respectively; P < 0.05), and the fractional 86Rb+ efflux decrement was -21 +/- 6% for glyburide (P < 0.005 vs. control islets) and -65 +/- 4% (not different from control) for tolbutamide. When glyburide- or tolbutamide-exposed islets were stimulated with the corresponding sulfonylurea, insulin release was impaired compared to that in control islets (P < 0.05), but, again, 86Rb+ efflux was impaired (P < 0.05) only in glyburide-exposed islets. When 45Ca2+ uptake was studied, the increase in glucose concentration from 2.8 to 16.7 mM increased calcium uptake in control islets from 1.76 +/- 0.58 to 7.27 +/- 1.36 pmol/islet.2 min (n = 4). Preexposure to 0.1 microM glyburide did not change calcium uptake at a glucose concentration of 2.8 mM (1.44 +/- 0.45 pmol/islet.2 min) but significantly reduced calcium uptake stimulated by 16.7 mM glucose (3.21 +/- 0.35 pmol/islet.2 min; n = 4; P < 0.005 compared to control islets). In contrast, preexposure to 100 microM tolbutamide did not change either basal or glucose-stimulated calcium uptake (1.44 +/- 0.45 and 6.90 +/- 0.81 pmol/islet.2 min, respectively; n = 4). These data show that in vitro chronic exposure of pancreatic islets to the sulfonylureas glyburide and tolbutamide impairs their ability to respond to a subsequent glucose or sulfonylurea stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Different effects of glucose and glyburide on insulin secretion in rat pancreatic islets pre-exposed to interleukin-1 beta. Possible involvement of K+ and Ca2+ channels.Diabetologia. 1993 Sep;36(9):791-6. doi: 10.1007/BF00400351. Diabetologia. 1993. PMID: 8405748
-
Fast reversibility of glucose-induced desensitization in rat pancreatic islets. Evidence for an involvement of ionic fluxes.Diabetes. 1996 Apr;45(4):502-6. doi: 10.2337/diab.45.4.502. Diabetes. 1996. PMID: 8603773
-
Insulin release from pancreatic islets of fetal rats mediated by leucine b-BCH, tolbutamide, glibenclamide, arginine, potassium chloride, and theophylline does not require stimulation of Ca2+ net uptake.Cell Calcium. 1989 Aug-Sep;10(6):441-50. doi: 10.1016/0143-4160(89)90035-3. Cell Calcium. 1989. PMID: 2505929
-
Effects of prolonged glucose stimulation on pancreatic beta cells: from increased sensitivity to desensitization.Acta Diabetol. 1996 Dec;33(4):253-6. doi: 10.1007/BF00571559. Acta Diabetol. 1996. PMID: 9033963 Review.
-
Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man.Diabetes Care. 1984 May-Jun;7 Suppl 1:25-34. Diabetes Care. 1984. PMID: 6376026 Review.
Cited by
-
Acute and long-term effects of nateglinide on insulin secretory pathways.Br J Pharmacol. 2004 May;142(2):367-73. doi: 10.1038/sj.bjp.0705766. Br J Pharmacol. 2004. PMID: 15155541 Free PMC article.
-
Glinide, but not sulfonylurea, can evoke insulin exocytosis by repetitive stimulation: imaging analysis of insulin exocytosis by secretagogue-induced repetitive stimulations.Exp Diabetes Res. 2009;2009:278762. doi: 10.1155/2009/278762. Epub 2009 Dec 28. Exp Diabetes Res. 2009. PMID: 20069052 Free PMC article.
-
Facilitating effects of berberine on rat pancreatic islets through modulating hepatic nuclear factor 4 alpha expression and glucokinase activity.World J Gastroenterol. 2008 Oct 21;14(39):6004-11. doi: 10.3748/wjg.14.6004. World J Gastroenterol. 2008. PMID: 18932278 Free PMC article.
-
Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.Diabetologia. 2011 Jul;54(7):1756-65. doi: 10.1007/s00125-011-2143-3. Epub 2011 Apr 12. Diabetologia. 2011. PMID: 21484213 Free PMC article.
-
Exposure to glibenclamide increases rat beta cells sensitivity to glucose.Br J Pharmacol. 2000 Mar;129(5):887-92. doi: 10.1038/sj.bjp.0703131. Br J Pharmacol. 2000. PMID: 10696086 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous